Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancer.

VEGF bevacizumab colorectal cancer prognosis visceral fat

Journal

Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659

Informations de publication

Date de publication:
22 May 2024
Historique:
received: 30 12 2022
revised: 19 04 2024
accepted: 22 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 24 5 2024
Statut: aheadofprint

Résumé

Visceral fat produces angiogenic factors such as vascular endothelial growth factor that promote tumoral growth. However, its influence on outcome for patients with advanced cancer treated with anti-angiogenic agents is controversial. The aim of this study was to determine whether visceral fat volume, visceral fat area and body mass index are associated with outcome in patients receiving first-line bevacizumab-based treatment for metastatic colorectal cancer. This multicenter prospective study included 103 patients with metastatic colorectal cancer who received first-line bevacizumab-based chemotherapy. Computed tomography was used to measure visceral fat volume and visceral fat area. Endpoints were tumoral response at 2 months, progression free survival and overall survival. Visceral fat volume and visceral fat area, but not body mass index, were significantly associated with better outcome. Using sex-specific median values progression free survival was significantly longer in patients with high visceral fat volume (13.2 versus 9.4 months; p=0.0043). In the same way, high visceral fat volume and visceral fat area were associated with a significantly better overall survival: 31.3 versus 20.5 months (p=0.0072) and 29.3 versus 20.5 months (p=0.0078), respectively. By multivariate analysis, visceral fat volume was associated with longer progression free survival and overall survival. This study demonstrates that a high visceral fat volume is associated with better outcome in patients receiving first-line bevacizumab-based chemotherapy for metastatic colorectal cancer.

Sections du résumé

BACKGROUND BACKGROUND
Visceral fat produces angiogenic factors such as vascular endothelial growth factor that promote tumoral growth. However, its influence on outcome for patients with advanced cancer treated with anti-angiogenic agents is controversial.
AIMS OBJECTIVE
The aim of this study was to determine whether visceral fat volume, visceral fat area and body mass index are associated with outcome in patients receiving first-line bevacizumab-based treatment for metastatic colorectal cancer.
METHODS METHODS
This multicenter prospective study included 103 patients with metastatic colorectal cancer who received first-line bevacizumab-based chemotherapy. Computed tomography was used to measure visceral fat volume and visceral fat area. Endpoints were tumoral response at 2 months, progression free survival and overall survival.
RESULTS RESULTS
Visceral fat volume and visceral fat area, but not body mass index, were significantly associated with better outcome. Using sex-specific median values progression free survival was significantly longer in patients with high visceral fat volume (13.2 versus 9.4 months; p=0.0043). In the same way, high visceral fat volume and visceral fat area were associated with a significantly better overall survival: 31.3 versus 20.5 months (p=0.0072) and 29.3 versus 20.5 months (p=0.0078), respectively. By multivariate analysis, visceral fat volume was associated with longer progression free survival and overall survival.
CONCLUSION CONCLUSIONS
This study demonstrates that a high visceral fat volume is associated with better outcome in patients receiving first-line bevacizumab-based chemotherapy for metastatic colorectal cancer.

Identifiants

DOI: 10.1016/j.clinre.2024.102380 PMID: 38788975
pubmed: 38788975
pii: S2210-7401(24)00101-3
doi: 10.1016/j.clinre.2024.102380
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102380

Informations de copyright

Copyright © 2024. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: TL: Consulting fees: Sanofi, Merck Serono, Servier, Pierre Fabre; Honoraria for lectures: AMGEN, Sanofi, Bayer, Servier, Pierre Fabre, Astra Zeneca; Travel expenses: Servier. OB: Consulting fees: Roche, Merck Serono, Astra Zeneca; Honoraria for lectures: Bayer, Servier, Pierre Fabre; Travel expenses: Roche. CB: Grants: Roche, Bayer; Consulting fees: Sanofi; Honoraria for lectures: Servier, Pierre Fabre, MSD. OL: Honoraria for lectures: Roche, Bracco. NC, JL, CLD, JPT, SM, CA, HT, CM, ET, JYD, RC, SL, BS and AB declare no conflict of interest.

Auteurs

Nicolas Cazeneuve (N)

Department of Radiology, Hôpital Trousseau, CHRU de Tours, 37044 Tours Cedex 09, France.

Olivier Bouché (O)

Department of Hepatogastroenterology, Hôpital Robert Debré, CHU de Reims, avenue Général Koenig, 51092 Reims Cedex, France.

Julie Leger (J)

INSERM CIC 1415, CHRU de Tours, CHRU de Tours, 37044 Tours Cedex 09, France.

Christophe Borg (C)

Department of Medical Oncology, Hôpital Jean Minjoz, CHRU de Besançon, 3 Boulevard Alexandre Fleming, 25000 Besançon, France.

Catherine Labbe-Devilliers (C)

Department of Radiology, ICO René Gauducheau, 44805 Saint-Herblain, France.

Olivier Lucidarme (O)

Department of Radiology, Hôpital Pitié-Salpétrière, APHP, 47, Boulevard de l'Hôpital, 75013 Paris, France.

Jean-Pierre Tasu (JP)

Department of Radiology, CHU de Poitiers, 2 rue Milétrie, 86021 Poitiers Cedex, France.

Sylvain Manfredi (S)

Department of Hepatogastroenterology and Digestive Oncology, CHU de Rennes, Hôpital Pontchaillou, 2 rue Henri Le Guilloux, 35033 Rennes Cedex 9, France.

Christophe Aubé (C)

Department of Radiology, CHU d'Angers, 4 rue Larrey 49100 Angers, France.

Hervé Trillaud (H)

Department of Diagnostic and Interventional Imaging, Hôpital Saint-André, CHU de Bordeaux, 1 rue Jean Burguet, 33000 Bordeaux, France.

Philippe Manzoni (P)

Department of Radiology, Hôpital Jean Minjoz, CHRU de Besançon, Hôpital Jean Minjoz, CHRU de Besançon, 3 Boulevard Alexandre Fleming, 25000 Besançon, France.

Claude Marcus (C)

Department of Radiology, Hôpital Robert Debré, CHU de Reims, avenue Général Koenig, 51092 Reims Cedex, France.

Eric Terrebonne (E)

Department of Hepatogastroenterology and Digestive Oncology, Hôpital du Haut Lêvèque, CHU de Bordeaux, avenue Magellan, 33604 Pessac Cedex, France.

Jean-Yves Douillard (JY)

Department of Medical Oncology, ICO René Gauducheau, 44805 Saint-Herblain, France.

Romain Chautard (R)

Department of Hepatogastroenterology and Digestive Oncology, Hôpital Trousseau, CHRU de Tours, 37044 Tours Cedex 09, France; UMR INSERM U 1069, Université de Tours, 10 Boulevard Tonnellé, 37000 Tours, France.

Sarah Lobet (S)

UMR INSERM U 1069, Université de Tours, 10 Boulevard Tonnellé, 37000 Tours, France.

Béatrice Scotto (B)

Department of Radiology, Hôpital Trousseau, CHRU de Tours, 37044 Tours Cedex 09, France.

Aurore Bleuzen (A)

Department of Radiology, Hôpital Bretonneau, CHRU de Tours, CHRU de Tours, 37044 Tours Cedex 09, France.

Thierry Lecomte (T)

Department of Hepatogastroenterology and Digestive Oncology, Hôpital Trousseau, CHRU de Tours, 37044 Tours Cedex 09, France; UMR INSERM U 1069, Université de Tours, 10 Boulevard Tonnellé, 37000 Tours, France. Electronic address: thierry.lecomte@med.univ-tours.fr.

Classifications MeSH